Why the study?
Does intravenous nitroglycerin combined with N-acetylcysteine reduce chest pain and acute myocardial infarction in patients with severe unstable angina pectoris unresponsive to conventional treatment?
Does intravenous nitroglycerin combined with N-acetylcysteine reduce chest pain and acute myocardial infarction in patients with severe unstable angina pectoris unresponsive to conventional treatment?
Combining intravenous nitroglycerin with N-acetylcysteine significantly reduced the incidence of acute myocardial infarction in patients with refractory unstable angina, though it increased the risk of symptomatic hypotension.
Answers are grounded in this paper and cite their sources.
Reduces myocardial infarction in refractory unstable angina; extends randomized evidence for nitroglycerin-N-acetylcysteine combination despite hypotension risk.
The vasodilator effects of nitroglycerin (NTG) are mediated via activation of guanylate cyclase; this process is believed to require the availability of free sulfhydryl groups. Previous studies in man have shown that the sulfhydryl donor N-acetylcysteine (NAC) potentiates the systemic and coronary vasodilator effects of NTG. Furthermore, interaction of NTG and NAC may lead to the formation of S-nitroso-NAC, which strongly inhibits platelet aggregation. The effects of intravenous NTG combined with intravenous NAC (5 g 6 hourly) were compared with those of intravenous NTG alone in a double-blind trial in 46 patients with severe unstable angina pectoris unresponsive to conventional treatment, which included calcium antagonists and cutaneous nitrates in all but one patient. Treatment with NTG/NAC (24 patients) and that with NTG alone (22 patients) was associated with a similar frequency of episodes of chest pain and of increments in NTG infusion rate for pain control (10 vs 17; p = NS). The NTG/NAC group had a significantly lower incidence of acute myocardial infarction than the NTG/placebo group (three vs 10 patients; p = .013). Symptomatic hypotension occurred frequently in the NTG/NAC group (seven vs 0 patients; p = .006). Lactate-pyruvate ratios and venous NTG concentrations were not significantly affected by NAC. Subsequently, another 20 consecutive patients were treated with intravenous NTG and continuously infused NAC (10 g/day). Seven remained pain free during the first 24 hr of NTG infusion; 11 required increments in NTG infusion rate for pain control. Acute myocardial infarction occurred in one patient, while none developed symptomatic hypotension.(ABSTRACT TRUNCATED AT 250 WORDS)
No takes yet. Share an insight, caveat, or question.
Horowitz et al. (1988) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: